Asthma News and Research

RSS

Asthma is a common inflammatory disease affecting the airways that leads to shortness of breath, coughing and wheezing. Symptoms range from mild to severe but are generally manageable with appropriate treatment.

Brown University neuroscience professor awarded EUREKA grant

Brown University neuroscience professor Gilad Barnea will receive a nearly $1.3 million, four-year federal grant toward development of a method to selectively monitor the activation of each of the five receptors for the neurotransmitter dopamine in the brain.

4 Sep 2009

SAFLUTAN launched in United Kingdom and Spain

Merck Sharp & Dohme (MSD) has launched SAFLUTAN (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today.

3 Sep 2009

Damprid's recommendations for tackling seasonal allergy

For America’s 60 million seasonal allergy sufferers, fall can be one of the most difficult times of year as ragweed begins to release its pollen into the air and mold and fungus spores increase due to the decay of leaves and other plants. Each ragweed plant produces one billion pollen grains per average season. This generally continues until the first frost, usually in October.

3 Sep 2009

Aerocrine’s NIOX MINO technology approved in Canada for treating asthma

Aerocrine AB (STO:AEROB) today announced that Health Canada’s Therapeutic Products Directorate has approved Aerocrine’s NIOX MINO® technology for use in treating asthma. Canada’s National Health Service may now begin using the NIOX MINO, a medical device that provides a measure of the degree of inflammation in the airways in a single breath.

3 Sep 2009

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Dainippon Sumitomo Pharma Co., Ltd. (“DSP”, TSE: 4506) and Sepracor Inc. (“Sepracor”, Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.

3 Sep 2009

Department of Health Care Services 2009 Gold Quality Award for SFHP

San Francisco Health Plan (SFHP), the City's community public health plan, today announced that it has received the Department of Health Care Services 2009 Gold Quality Award, ranking the plan as a leader in quality care throughout the state of California for Medi-Cal managed care plans.

2 Sep 2009

Selexis SA and NKT Therapeutics sign research services agreement

Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM).

2 Sep 2009

LUNA surgical procedure did not alleviate chronic pelvic pain in women

A surgical procedure known as LUNA (laparoscopic uterosacral nerve ablation) did not result in improvements in chronic pelvic pain, painful menstruation, painful sexual intercourse or quality of life when compared with laparoscopic surgery that does not interrupt pelvic nerve connections, according to a study in the September 2 issue of JAMA.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology.

2 Sep 2009

New clinical predictors required to determine future asthma attacks

Screening tests used to predict asthma activity in patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens, UT Southwestern Medical Center physician report.

1 Sep 2009

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Many Rite Aid pharmacists have already been giving regular seasonal flu shots following the Centers for Disease Control and Prevention (CDC) advice that anyone who wishes to reduce the risk of getting the regular seasonal flu get a flu shot as soon as they are available.

31 Aug 2009

Seasonal flu shots to be available daily without an appointment at more than 500 MinuteClinic locations

CVS/pharmacy, the nation's leading retail pharmacy, and MinuteClinic, the largest retail health care clinic provider in the U.S., today announced the availability of seasonal flu vaccinations and urged Americans to protect themselves early against the flu. CVS/pharmacy and MinuteClinic are divisions of CVS Caremark (NYSE: CVS), the largest provider of prescriptions in the country.

31 Aug 2009

Genetic variants on chromosome 9q may influence asthma development in Mexican children

Genetic variants in a region on chromosome 9q may influence asthma development in Mexican children, according to research published in the August 28 issue of the open-access journal PLoS Genetics.

28 Aug 2009

Bus tour campaign to raise the awareness of patient assistance programs

The 'Help is Here Express' bus tour will be stopping in Virginia throughout the week of August 31 - September 3 at various cities in order to help uninsured and financially-struggling Virginians access information on programs that provide prescription medicines for free or nearly free.

28 Aug 2009

Licensing agreement between Orexo and Novartis signed to develop and commercialise a novel product related to Orexo’s OX17 program

Orexo (STO: ORX) announces it has signed an exclusive worldwide licensing agreement with a Novartis affiliate to develop and commercialise a novel product related to Orexo’s OX17 program.

28 Aug 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Four medical groups of Resurrection Health Care Preferred earn nine blue stars in the 2009 Blue Star Report

Three out of four medical groups of Resurrection Health Care Preferred (RHCP) have earned nine blue stars, a perfect score, in the 2009 Blue Star Report -- an annual ranking of doctors in medical groups from Blue Cross Blue Shield of Illinois.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that asthma patients in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

27 Aug 2009

Asthma News and Research

Further Reading

Brown University neuroscience professor awarded EUREKA grant

SAFLUTAN launched in United Kingdom and Spain

Damprid's recommendations for tackling seasonal allergy

Aerocrine’s NIOX MINO technology approved in Canada for treating asthma

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Department of Health Care Services 2009 Gold Quality Award for SFHP

Selexis SA and NKT Therapeutics sign research services agreement

LUNA surgical procedure did not alleviate chronic pelvic pain in women

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

New clinical predictors required to determine future asthma attacks

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Seasonal flu shots to be available daily without an appointment at more than 500 MinuteClinic locations

Genetic variants on chromosome 9q may influence asthma development in Mexican children

Bus tour campaign to raise the awareness of patient assistance programs

Licensing agreement between Orexo and Novartis signed to develop and commercialise a novel product related to Orexo’s OX17 program

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Four medical groups of Resurrection Health Care Preferred earn nine blue stars in the 2009 Blue Star Report

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News